## **Alexey Pshonkin**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3380646/publications.pdf

Version: 2024-02-01

2258059 2053705 36 39 3 5 citations g-index h-index papers 36 36 36 50 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. Blood Advances, 2023, 7, 953-962.	5.2	8
2	De novo <i>TP53</i> germline activating mutations in two patients with the phenotype mimicking Diamond–Blackfan anemia. Pediatric Blood and Cancer, 2022, 69, e29558.	1.5	6
3	Efficacy and toxicity of the treatment of children and adolescents with Hodgkin Lymphoma by GPOH-HD-2002 protocol. Pediatric Hematology/Oncology and Immunopathology, 2019, 18, 49-54.	0.3	3
4	Deep veins thrombosis in children with blood diseases. Oncogematologiya, 2019, 14, 20-30.	0.3	3
5	Specifities of the storage pool and morphology of platelets in children with unspecified hemorrhagic syndrome. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 58-65.	0.3	2
6	Platelet phenotype in children with ANKRD26-related thrombocytopenia. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 65-73.	0.3	2
7	Clericusio syndrome (poikiloderm with neutropenia). Pediatric Hematology/Oncology and Immunopathology, 2019, 18, 96-103.	0.3	2
8	Use of romiplostim for newly diagnosed immune thrombocytopenia in children. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 18-26.	0.3	2
9	VENOUS THROMBOSIS IN CHILDREN AND ADOLESCENTS WITH HODGKIN'S LYMPHOMA. Pediatriia, 2018, 97 30-36.	'0.2	2
10	Rosay–Dorfman – like lymphadenopathy in a patient with Wiskott–Aldrich syndrome: diagnostic difficulties. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 108-115.	0.3	2
11	The experience of using the Brentuximab vedotin in the treatment of children and young adults with primary refractory course and relapses of Hodgkin's lymphoma. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 47-52.	0.3	2
12	The first experience of using MEK inhibitors for type 1 neurofibromatosis in children in the Russian Federation in a hospital for short-term treatment at the National Medical Research Center. Russian Journal of Pediatric Hematology and Oncology, 2021, 8, 85-92.	0.3	1
13	Efficacy and safety of ruxolitinib in ineffective erythropoiesis suppression as a pretransplantation treatment for pediatric patients with betaâ€thalassemia major. Pediatric Blood and Cancer, 2021, 68, e29338.	1.5	1
14	CHRONIC PAIN SYNDROME IN PEDIATRIC ONCOLOGICAL PALLIATIVE PATIENTS IN RUSSIA. Pediatriia, 2019, 98, 115-121.	0.2	1
15	A case report of atypical malignant melanotic neuroectodermal tumor of infancy. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 168-177.	0.3	1
16	Immune tolerance induction with a high-purity von Willebrand factor containing plasma-derived factor VIII concentrate in a child with hemophilia A with inhibitors. Pediatric Hematology/Oncology and Immunopathology, 2022, 21, 122-126.	0.3	1
17	Pseudotumor of the maxilla as first presentation of hemophilia B in a 1-year-old male. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 156-159.	0.3	0
18	Rare CVID-like phenotype of autoimmune lymphoproliferative syndrome. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 170-179.	0.3	0

#	Article	IF	CITATIONS
19	EVALUATION OF THE SENSITIVITY AND SPECIFICITY OF THE PEDIATRIC BLEEDING QUESTIONNAIRE IN VARIOUS HEMORRHAGIC DISORDERS. Pediatriia, 2021, 100, 35-41.	0.2	0
20	Evans syndrome in children: the results of a retrospective study of 54 patients. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 74-83.	0.3	0
21	INTEGRATION OF PRIMARY PALLIATIVE CARE AND PEDIATRIC ONCOLOGY SERVICES USING SHORT-TERM HOSPITAL FACILITIES: EXPERIENCE OF ONE CENTER. Pediatriia, 2021, 100, 200-207.	0.2	0
22	Von Willebrand factor multimeric assay: novel diagnostics capabilities. Russian Journal of Pediatric Hematology and Oncology, 2021, 8, 35-41.	0.3	0
23	RESULTS OF A RETROSPECTIVE COMPARATIVE ANALYSIS OF THE MANIFESTATIONS AND SEVERITY OF HEMORRHAGIC SYNDROME IN CHILDREN WITH GLANZMANNâ $\in$ <sup>™</sup> S THROMBASTHENIA. Pediatriia, 2021, 100, 109-116.	0.2	0
24	Incidence of venous thromboembolism in children with primary lymphomas. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 46-50.	0.3	0
25	Hemorrhagic thrombocytopathy with defective signal transduction CalDAG-GEFI. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 126-131.	0.3	0
26	EARLY DIAGNOSIS OF DUCHENNE MUSCULAR DYSTROPHY IN A CHILD WITH CONGENITAL INFANTILE FIBROSARCOMA OF RIGHT SHOULDER SOFT TISSUES. Pediatriia, 2019, 98, 275-281.	0.2	0
27	SPECTRUM OF DIFFERENTIAL DIAGNOSIS OF IMMUNE THROMBOCYTOPENIA IN CHILDREN. Pediatriia, 2019, 98, 62-71.	0.2	0
28	Pharmacokinetics of 13-cis-Retinoic acid in high-risk neuroblastoma patients. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 20-31.	0.3	0
29	Results of extended phenotyping of von Willebrand disease in the remote diagnostic program in children. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 102-106.	0.3	0
30	Essential thrombocythemia in children and adolescents â€" analysis of 31 cases. Gematologiya I Transfuziologiya, 2021, 66, 480-498.	0.6	0
31	Factor XIII deficiency – where we can save. Russian Journal of Pediatric Hematology and Oncology, 2022, 8, 90-94.	0.3	0
32	Congenital combined vitamin K-dependent clotting factors deficiency: case reports. Pediatric Hematology/Oncology and Immunopathology, 2022, 21, 104-109.	0.3	0
33	FACTOR XII DEFICIENCY IN CHILDREN: COAGULOPATHY OR LABORATORY FINDING. Pediatriia, 2022, 101, 50-55.	0.2	0
34	A case report of lymphoepithelioma-like carcinoma in an adolescent. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 134-138.	0.3	0
35	Two rare cases of cystic angiomatosis and a literature review. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 148-153.	0.3	0
36	The THROMB-HEM study: first results and future prospects. Pediatric Hematology/Oncology and Immunopathology, 2022, 21, 61-65.	0.3	0

3